STTK Shattuck Labs, Inc. Insider Trading

Director Clay B Siegall purchases 62,500 STTK shares at $4.00 amid -82.5% annual revenue decline and $-14.8M net loss

Clay B Siegall, a Director, acquired 62,500 shares at $4.00 on 2026-06-09 for $250,000.00, increasing his holdings from 256.1K to 318.6K shares (+24.4%). The timing occurs within a severely stressed context: the company reported $0.00 revenue in its latest quarter, generated $-14.8M net income over its most recent full fiscal year, and experienced -82.5% annual revenue growth. The stock has declined -36.9% over 30 days and -30.2% over 90 days from the current price of $4.18, sitting -49.8% below its 52-week high of $8.33. While Siegall's cross-ticker track record shows 11 prior buys averaging +10.2% 30-day returns with a 60.00% 90-day win rate, this current acquisition occurs amid clear fundamental deterioration and sharp price weakness that distinguishes it from his historical buy pattern context. The size of the purchase—representing a material 24.4% increase in his direct holdings—reflects a substantial personal commitment at depressed price levels during a period of operational distress.

Director Ashiya Mona buys 6,306,127 shares at $0.87 on 2025-08-25, investing $5,471,826.40 amid stock down 73.9% from 52-week high

Director Ashiya Mona purchased 6.31M shares across 2 separate transactions on 2025-08-25 at a blended average price of $0.87, committing approximately $5.5M. The purchase occurred when STTK was trading 73.9% below its 52-week high of $3.87, though the stock is up 38.0% over the prior 30 days. Notably, Mona's cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 100.00%, indicating her historical sell decisions have been followed by stock declines—a pattern that does not extend to buy decisions in the available metrics. The company reported zero revenue in the latest quarter and a net loss of $12.5M while unprofitable over its most recent full fiscal year, creating substantial execution risk alongside the deeply depressed valuation.

ORBIMED ADVISORS LLC (Director) bought 6,306,127 shares at $0.87 on 2025-08-25 for $5,471,826.40 in two transactions

ORBIMED ADVISORS LLC executed two separate purchases totaling 6,306,127 shares at $0.87 for $5,471,826.40, bringing the director's holding to 1,051,021 shares post-transaction. The acquisition price of $0.87 is 13.9% below the current price of $1.01, and well above the 52-week low of $0.73, though the stock remains -73.9% below its 52-week high of $3.87. Shattuck Labs is unprofitable with net income of -$12,458,000 in its most recent fiscal year and $0.00 latest-quarter revenue, though the company achieved +245.3% annual revenue growth (FY vs prior FY), suggesting business scaling despite near-term losses. The director's cross-ticker track record shows 2 prior buys with an 0.00% 90-day win rate (average 90d return -35.4%), indicating past open-market purchases at other companies have underperformed in the 90-day window. This purchase's significance is moderated by the unprofitable operational profile and the director's limited buy-side success track record across other securities.

Director Jeremy Green buys and sells 133,371 shares at $1.25 same day

Jeremy Green (Director) executed a buy and sell of the same quantity of shares (133,371 shares at $1.25) on the same date (2024-12-04). Each transaction totaled $166,713.75, resulting in no net change to his position relative to the transaction pair itself. This simultaneous buy-sell of identical size and price represents a wash transaction with no material economic impact. His post-transaction holdings stand at 5,539,724 shares.

CEO Schreiber Taylor bought 36,500 shares of STTK at $1.21, doubling his stake to 71,002 shares amid -88.7% 52-week decline.

CEO Schreiber Taylor purchased 36,500 shares at $1.21 on 2024-10-07, increasing his holdings by 105.8% from 34,502 to 71,002 shares. The purchase occurred with the stock trading 88.7% below its $11.18 52-week high and down 64.0% over the preceding 30 days. His prior open-market purchase at this company on 2024-06-26 posted a +6.5% 90-day return, suggesting some pattern of entry timing at STTK. However, the company's fundamentals show severe deterioration: it generated only $1.6M in revenue in its latest quarter, reported -$21.6M in net income, and remains unprofitable despite 154.1% annual revenue growth. The extreme valuation pressure—stock at -88.7% from 52-week highs—combined with substantial quarterly losses creates material execution risk that extends beyond typical valuation multiples.

Director Tyler Brous purchases 8,416 shares for $32,768.24 across 2 transactions at STTK as stock declines 45.9% in 30 days.

Tyler Brous, a Director at Shattuck Labs, executed 2 separate purchases totaling 8,416 shares for $32,768.24 at a blended average price of $3.89 on June 27-28, 2024, increasing his holdings from 229,672 shares to 238,088 shares (+3.7%). This buy activity occurs against a backdrop of material stock weakness: the company's shares are trading at $3.99, down 45.9% over the prior 30 days and 54.2% over 90 days, placing the stock 64.3% below its 52-week high of $11.18. The company remains unprofitable with a net loss of $18,504,000.00 in its most recent full fiscal year, although it has demonstrated strong revenue growth of +154.1% year-over-year and generated $1,115,000.00 in quarterly revenue. The buy appears discretionary and open-market rather than part of a pre-scheduled plan, though the small position increase relative to the existing 238.1K share base suggests a measured approach in the current valuation environment.

STTK CEO Schreiber Taylor bought 14,400 shares at $3.47; holdings now 34,502 shares (+71.6% increase)

CEO Schreiber Taylor purchased 14,400 shares at $3.47 on 2024-06-26, increasing his position by 71.6% to 34,502 shares total. The transaction occurred at a price that has since declined significantly: the stock currently trades at $3.79 (down 66.1% from the 52-week high of $11.18) and the 90-day trend is down 57.6%. Shattuck Labs remains unprofitable with net income of $-18.5M on quarterly revenue of $1.1M, though the company demonstrated strong annual revenue growth of +154.1%. The CEO's substantial accumulation at depressed price levels during a period of significant stock decline warrants examination of whether this reflects conviction in the business recovery or other strategic considerations, particularly given the company's ongoing losses and steep drawdown from recent highs.